Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups

Thomas Powles, Director of Barts Cancer Centre, shared a post on X/Twitter:

“Enfortumab, Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence (RR), Progression-free survival (PFS) and Overall Survival (OS) in all subgroups. This includes subsets such as lymph node disease, liver metastasis, PD-L1 status, upper tract disease, and platinum eligibility. This positive data underlines Enfortumab Vedotin and Pembrolizumab as a new standard of care.”

Source: Thomas Powles/X